Advertisement
"The recommendations of these two leading independent proxy advisory firmsconfirm our Board of Directors' unanimous view that the proposed asset sale isin the best interests of Nabi stockholders," said Dr. Leslie Hudson, InterimPresident and Chief Executive Officer of Nabi Biopharmaceuticals. "We urgeall of our stockholders to vote "FOR" the proposed asset sale today."
Advertisement
Stockholders are encouraged to read the Company's definitive proxymaterials in their entirety as they provide, among other things, a detaileddiscussion of the process that led to the proposed asset sale and reasonsbehind the Board of Directors' unanimous recommendation that stockholders vote"FOR" the proposed asset sale. Stockholders who have questions about theasset sale or need assistance in submitting their proxy or voting their sharesshould contact the Company's proxy solicitor, Morrow & Co., Inc., toll free at1-800-662-5200.
The Company's special meeting of stockholders is scheduled for Thursday,November 8, 2007, at 10:00 a.m., local time, at the Bethesda Marriott, 5151Pooks Hill Road, Bethesda, Maryland. Stockholders of record at the close ofbusiness on October 10, 2007 are entitled to notice of and to vote at thespecial meeting.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in poweringthe immune system to develop and, in certain areas, market products thattarget serious medical conditions in the areas of hepatitis and transplants,gram positive bacterial infections and nicotine addiction. We are a verticallyintegrated company with sales of antibodies and other biologics, includingNabi-HB(R) [Hepatitis B Immune Globulin (Human)], a pipeline of products invarious stages of development and a state-of-the-art manufacturing capability.The company operates through two strategic business units: Nabi Biologics andNabi Pharmaceuticals. Nabi Biologics has responsibility for the company'sprotein and immunological products and development pipeline, including Nabi-HB. Nabi Pharmaceuticals is responsible for the NicVAX(R) (Nicotine ConjugateVaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide ConjugateVaccine) development programs. For a complete list of pipeline products,please go to: http://www.nabi.com/pipeline/index.php. In September 2007, Nabiannounced that it had entered into a definitive agreement with Biotest AG tosell the Nabi Biologics strategic business unit to Biotest PharmaceuticalsCorporation, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], andother plasma business assets, including Nabi's state-of-the-art plasma proteinproduction plant, and nine FDA-certified plasma collection centers across theU.S. The acquisition also will include certain of Nabi's Corporate SharedServices group assets and the company's Boca Raton, Florida headquarters andother facilities, as well as the assumption of certain liabilities, and isexpected to close by the end of the year. The company is headquartered in BocaRaton, Florida. For additional information about Nabi Biopharmaceuticals,please visit our Web site: http://www.nabi.com.
SOURCE Nabi Biopharmaceuticals
